Medicare Price Negotiation, Generic Availability, and Out-of-Pocket Costs for Cardiac Medications - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Medicare Drug Price Negotiations, Generic Access, and Patient Costs for Cardiovascular Medications

  • By

  • Celeste W. Franklin

  • Nathalia Ladino

  • Neha Parvathala

  • Gary C. N. Hettinger

  • Harmony R. Reynolds

  • Samrachana Adhikari

  • Saul Blecker

  • Amrita Mukhopadhyay

  • November 19, 2026

Share

  • 1

    This repeated cross-sectional study used a difference-in-differences approach to assess Medicare plan-level out-of-pocket costs before and after price negotiation began.

  • 2

    The analysis included 6215 Medicare drug coverage plans and compared negotiated cardiovascular medications with nonnegotiated PCSK9 inhibitors and ticagrelor.

  • 3

    Negotiation was associated with a $56.63 decrease in 30-day out-of-pocket costs for medications without a generic alternative (95% CI, $55.48-$57.78).

  • 4

    For medications with a generic alternative, negotiation was associated with a $7.46 decrease in 30-day out-of-pocket costs (95% CI, $6.05-$8.78).

  • 5

    The study covered the first year of negotiation and plan-level costs only, excluding beneficiary-level data, clinical outcomes, and other contemporaneous policy changes.

Original Source(s)

Related Content